LGM Pharma is a Micafungin CAS# 235114-32-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
Questions? Call our customer API support number 1-(800)-881-8210.
LGM Pharma offers this active ingredient but not the finished dosage forms.
CAS No: 235114-32-6
ATC Code: J02AX05
Chemical Formula: C56H71N9O23
Molecular Weight: 1270.28
Assay/Purity: Typically NLT 98%
Micafungin is indicated for treating the following conditions:CandidemiaAcute disseminated candidiasis Invasive Candida infectionsProphylaxis of Candida infections in patients who have undergone hematopoietic stem cell transplantationsEsophageal candidiasisAlternative therapy for oropharyngeal candidiasis Combination therapy alongside other antifungal medications to treat invasive aspergillosis
As a semisynthetic lipopeptide Micafungin is an antifungal agent. Micafungin works by inhibiting the enzyme needed for fungal cell-wall synthesis.
Mode of Action:
Micafungin is a glucan synthesis inhibitor of the echinocandin structural class and can be used safely alongside other drugs such as HIV and transplant drugs.
In vitro Micafungin is highly protein bound with the primary binding protein being albumin. The half-life of Micafungin is between 14 and 17 hours.
Dose-limiting toxicity has not been found in adult patient clinical trials. The minimum lethal dose of Micafungin is 125 mg/kg in rats, which is 8.1 times the recommended clinical human dose. Severe adverse effects from Micafungin are uncommon, with patients reporting minor side effects like headache, mild itching, slight nausea and flushing.
Drugs. 2008;68(15):2225-55.Journal of Pediatric Hematology/Oncology:July 2015 – Volume 37 – Issue 5 – p e285–e291
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
API’s From Quality Manufacturers:
Cost effective materials based on specific requirements
Small quantities for initial research and larger development quantities towards product commercialization
Technical packages, letters of access to filed DMFs